Advertisement
| ascvd pooled cohort risk assessment: Stroke-Vascular Diseases W.Wolfgang Fleischhacker, David J. Brooks, 2002-11-07 Atherosclerosis, the underlying cause of heart attacks, strokes and peripheral vascular disease, is one of the major killers in the world. By 2020 WHO statistics indicate that it will be the most common cause of morbidity and mortality in both the industrialised world and the underdeveloped world. The disease develops slowly over many years in the innermost layer of large and medium-sized arteries (Fig. 1) (Scott, 1995; Ross, 1999; Naumova and Scott, 2000; Glass and Witztum, 2001; Libby, 2001). It does not usually become manifest before the fourth of fifth decade, but then often strikes with devas tating suddenness. Fifty per cent of individuals still die (25 per cent immedi ately) from their first heart attack; and morbidity from coronary heart disease and stroke is very significant. The disease has a profound impact on health care services and on industrial economies. The lesions of atherosclerosis Autopsy studies show that in humans atherosclerosis begins in the first and second decade of life. A similar disease can be produced in experimental animals, where diet and genetics can be manipulated to produce identical lesions. The earliest lesions are fatty streaks. These consist of an accumulation of lipid-engorged macrophages (foam cells) and T and B lymphocytes in the arterial intima. With time, the fatty streaks progress to intermediate lesions, composed of foam cells and smooth muscle cells. |
| ascvd pooled cohort risk assessment: Preventive Cardiology: A Practical Approach, Second Edition Nathan D. Wong, Henry Black, Julius M. Gardin, 2005 PREVENTIVE CARDIOLOGY is the premier source of clinically relevant information on the prevention of coronary heart disease. Thoroughly updated by international experts, the book discusses screening, risk factors, prevention in special populations, and primary and secondary prevention in the context of the daily practice of medicine. PREVENTIVE CARDIOLOGY is a must have for cardiologists and primary care physicians. Review of the first edition: Excellent...Structured in a way that invites the reader to use it as a comprehensive reference...The combination of theory and guidelines with a practical approach to the patient at risk for cardiovascular diseases is a strength. The New England Journal of Medicine |
| ascvd pooled cohort risk assessment: Management of Dyslipidemia Wilbert S. Aronow, 2021-07-21 Dyslipidemia is a major risk factor for cardiovascular events, cardiovascular mortality, and all-cause mortality. The earlier in life dyslipidemia is treated, the better the prognosis. The current book is an excellent one on dyslipidemia written by experts on this topic. This book includes 12 chapters including 5 on lipids, 4 on hypercholesterolemia in children, and 3 on the treatment of dyslipidemia. This book should be read by all health care professionals taking care of patients, including pediatricians since atherosclerotic cardiovascular disease begins in childhood. |
| ascvd pooled cohort risk assessment: Coronary Primary Prevention Trial , 1984 |
| ascvd pooled cohort risk assessment: Pericardial Disease J. Soler-Soler, G. Permanyer, J. Sagristà-Sauleda, 2012-12-06 In November 1986, I was invited to attend a symposium held in Barcelona on Diseases of the Pericardium. The course was directed by Dr. J. Soler-Soler, director of Cardiology at Hospital General Vall d'Hebron in Barcelona. During my brief but delightful visit to this institution, my appreciation of the depth and breadth of study into pericardial diseases, carried out by Dr. Soler and his group, grew into the conviction that these clinical investigators have accumulated a wealth of information concerning pericardial diseases, and that investigators and clinicians practicing in English speaking countries would greatly profit from ready access to the results of the clinical investiga tions into pericardial disease carried out in Barcelona. The proceedings of the Barcelona conference were published in a beauti fully executed volume in the Spanish language edited by Dr. Soler and pro duced by Ediciones Doyma. Because I believe that this work should be brought to the attention of the English speaking scientific and clinical com munities, I encouraged Dr. Soler to have the book translated into English. I knew that this task could be accomplished and that the book would be trans lated into good English without change of its content. My confidence was based upon a translation of my own book, The Pericardium, into Spanish undertaken by Dr. Permanyer, who is a contributor and co-editor of the pre sent volume. |
| ascvd pooled cohort risk assessment: Clinical Epidemiology Alvan R. Feinstein, 1985 |
| ascvd pooled cohort risk assessment: Secondhand Smoke Exposure and Cardiovascular Effects Institute of Medicine, Board on Population Health and Public Health Practice, Committee on Secondhand Smoke Exposure and Acute Coronary Events, 2010-02-21 Data suggest that exposure to secondhand smoke can result in heart disease in nonsmoking adults. Recently, progress has been made in reducing involuntary exposure to secondhand smoke through legislation banning smoking in workplaces, restaurants, and other public places. The effect of legislation to ban smoking and its effects on the cardiovascular health of nonsmoking adults, however, remains a question. Secondhand Smoke Exposure and Cardiovascular Effects reviews available scientific literature to assess the relationship between secondhand smoke exposure and acute coronary events. The authors, experts in secondhand smoke exposure and toxicology, clinical cardiology, epidemiology, and statistics, find that there is about a 25 to 30 percent increase in the risk of coronary heart disease from exposure to secondhand smoke. Their findings agree with the 2006 Surgeon General's Report conclusion that there are increased risks of coronary heart disease morbidity and mortality among men and women exposed to secondhand smoke. However, the authors note that the evidence for determining the magnitude of the relationship between chronic secondhand smoke exposure and coronary heart disease is not very strong. Public health professionals will rely upon Secondhand Smoke Exposure and Cardiovascular Effects for its survey of critical epidemiological studies on the effects of smoking bans and evidence of links between secondhand smoke exposure and cardiovascular events, as well as its findings and recommendations. |
| ascvd pooled cohort risk assessment: Prevention Of Cardiovascular Disease Eastern Mediterranean Region STYLUS PUB LLC, World Health Organization, 2007-08-09 |
| ascvd pooled cohort risk assessment: ASPC Manual of Preventive Cardiology Ezra A. Amsterdam, Nathan Wong, Ezra Amsterdam, MD, Roger Blumenthal, MD, FACC, FAHA, 2014-10-23 Endorsed by the American Society for Preventive Cardiology, this highly practical resource focuses on the application of current guidelines and practice standards in the clinical management of cardiovascular risk factors. The Manual presents concise descriptions of each major cardiovascular risk factor, and practical, to-the-point discussions of current best practices in clinical management. In addition, the Manual includes chapters on peripheral arterial disease, stroke, smoking, contemporary cardiovascular imaging, heart failure, metabolic syndrome, thrombosis, nutrition, special populations, novel risk factors, and psychosocial stress. Throughout the Manual, recommendations are based on the most recent prevention guidelines of the American College of Cardiology and American Heart Association, including those on Risk Assessment, Lifestyle Recommendations, Blood Cholesterol, and Obesity, as well as the new guidelines on Hypertension. Chapter authors are recognized leaders in each area of practice, and special efforts have been made by the authors and editors to ensure that the content of all chapters is as up-to-date as possible. Key Features: Presents a highly practical focus on the application of current guidelines and practice standards regarding cardiovascular risk factors Recommendations based on the most recent prevention guidelines Authored by recognized leaders in the field Covers all major cardiovascular risk factors, key methodologies in risk assessment, and special issues regarding specific patient populations |
| ascvd pooled cohort risk assessment: Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult Treatment Panel II). National Cholesterol Education Program (U.S.). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 1993 |
| ascvd pooled cohort risk assessment: Oxford Textbook of Global Public Health Roger Detels, Martin Gulliford, Quarraisha Abdool Karim, Chorh Chuan Tan, 2017 Sixth edition of the hugely successful, internationally recognised textbook on global public health and epidemiology, with 3 volumes comprehensively covering the scope, methods, and practice of the discipline |
| ascvd pooled cohort risk assessment: The Price of Smoking Frank A. Sloan, Jan Ostermann, Christopher Conover, Donald H. Taylor, Gabriel Picone, 2006-08-11 What does a pack of cigarettes cost a smoker, the smoker's family, and society? This longitudinal study on the private and social costs of smoking calculates that the cost of smoking to a 24-year-old woman smoker is $86,000 over a lifetime; for a 24-year-old male smoker the cost is $183,000. The total social cost of smoking over a lifetime—including both private costs to the smoker and costs imposed on others (including second-hand smoke and costs of Medicare, Medicaid, and Social Security)—comes to $106,000 for a woman and $220,000 for a man. The cost per pack over a lifetime of smoking: almost $40.00. The first study to quantify the cost of smoking in this way, or in such depth, this accessible book not only adds a weapon to the arsenal of antismoking messages but also provides a framework for assessment that can be applied to other health behaviors. The findings on the effects of smoking on Medicare and Medicaid will be surprising and perhaps controversial, for the authors estimate the costs to be much lower than the damage awards being paid to 46 states as a result of the 1998 Master Settlement Agreement. |
| ascvd pooled cohort risk assessment: Lipid Management Hussein Yassine, 2015-03-03 This timely, concise title provides an important update on clinical lipid management. Using information from recent clinical trials and in special populations, the book begins by offering an easy-to-read overview of LDL, HDL, and triglyceride metabolism and the genetics of lipid disorders. The link between inflammation and lipids, and how this relates to atherosclerosis development, is also addressed, as are the measures of subclinical atherosclerosis in patients with abnormal lipid levels. Lipid abnormalities in children, with a particular focus on vulnerable populations (with an emphasis on ethnicity and childhood obesity), are covered. The treatment goals and approaches for managing lipids in the clinic are thoroughly discussed, emphasizing the important role of statin use and addressing controversies of lipid management in special populations such as heart failure, end stage kidney disease and fatty liver disease. Of special note, an important update on how new HIV medications impact lipid levels is provided. In all, Lipid Management: From Basics to Clinic, is an invaluable, handy resource for understanding changes in lipids in different populations and for sharpening the clinical approach to managing complicated lipid cases. |
| ascvd pooled cohort risk assessment: Statin-Associated Muscle Symptoms Paul D. Thompson, Beth A. Taylor, 2020-01-25 This book provides an overview of statin-associated muscle symptoms (SAMS) from clinical presentation to treatment and possible metabolic causes. It examines the risk factors, presentations, diagnosis and differential diagnosis, clinical management, and financial costs of SAMS. The book also highlights patients’ perspectives on SAMS such as the psychosocial, emotional, and societal factors influencing their perceptions and experiences. Finally, the book presents the results of observational and clinical trials on the prevalence of SAMS, clinical trials for treatments, and potential future research approaches for improving the understanding and treatment of SAMS. A key addition to the Contemporary Cardiology series, Statin-Associated Muscle Symptoms is an essential resource for physicians, medical students, residents, fellows, and allied health professionals in cardiology, endocrinology, pharmacotherapy, primary care, and health promotion and disease prevention. |
| ascvd pooled cohort risk assessment: Risk Assessment in Oral Health Iain L.C. Chapple, Panos N. Papapanou, 2020-03-25 This book is a wide-ranging guide to risk assessment and risk-based prevention in oral health and dentistry. Readers will find clear explanations of the principles, models, and tools of risk assessment, as well as practical information on risk assessment in relation to periodontal disease, caries, tooth wear, and oral cancer. The lessons that the oral healthcare profession can learn from experiences regarding risk assessment in primary medical care practice, particularly in cardiovascular and diabetes medicine, are highlighted. The closing section focuses specifically on implementation of risk assessment within the dental practice, including training of the oral healthcare team and the need to take into account medicolegal considerations. The book is a very timely addition to the literature, given the move towards wellness- rather than repair-based models of healthcare in Europe and North America and the focus of dental contracts on risk-driven care pathways. It will be of high value for not only practitioners but also professionals and healthcare funding bodies. |
| ascvd pooled cohort risk assessment: Decision Making in Health and Medicine M. G. Myriam Hunink, Milton C. Weinstein, Eve Wittenberg, 2014-10-16 A guide for everyone involved in medical decision making to plot a clear course through complex and conflicting benefits and risks. |
| ascvd pooled cohort risk assessment: Textbook of Stroke Medicine Michael Brainin, Wolf-Dieter Heiss, Susanne Tabernig, 2014-09-11 Fully revised throughout, the new edition of this concise textbook is aimed at doctors preparing to specialize in stroke care. |
| ascvd pooled cohort risk assessment: Drug Treatment of Hyperlipidemia B. Rifkind, 1991-05-20 Originally published in 1991, ' Drugs Treatment of Hyperlipidemia' is a collection of essays that include studies on lipid metabolism, diagnosis of lipoprotein disorders, detection and treatment of dyslipoporteinemia and trials of lipid lowering drugs amongst its topics |
| ascvd pooled cohort risk assessment: OECD Health Policy Studies Cardiovascular Disease and Diabetes: Policies for Better Health and Quality of Care OECD, 2015-06-17 This report examines how countries perform in their ability to prevent, manage and treat cardiovascular disease (CVD) and diabetes. |
| ascvd pooled cohort risk assessment: Prevention of Myocardial Infarction JoAnn E. Manson, 1996 Coronary heart disease remains the leading cause of death in both men and women in most industrialized countries. Yet it is largely preventable, and health care providers can acquire the skills to help their patients reduce their risks substantially. Traditional risk factors such as cigarette smoking, hypercholesterolimia, hypertension, sedentary lifestyle, obesity and glucose intolerance explain a major proportion of coronary events. Recent evidence also suggests important adjunctive roles for hormone replacement therapy in postmenopausal women, and aspirin prophlaxis in individuals at high risk of a first myocardial infarction. Emerging evidence indicates an important role for diet in the prevention of heart disease. Although the importance of lifestyle and behavioral modifications may well be known among physicians and other health-care providers, the implementation of this knowledge has been limited. One reason is that the information supporting the value, feasibility and cost-effectiveness of risk-reduction strategies has not been previously synthesized and made widely available to health-care providers in office and community settings. Prevention of Myocardial Infarction fills these critical gaps by providing a state-of-the-art compendium of the scientific evidence on the efficacy of coronary disease prevention, while focusing on helping clinicians develop intervention skills to utilize available knowledge. Chapters by leading authorities in cardiovascular epidemiology, clinical cardiology, cost-effectiveness analysis, and public health translate the theory of preventive cardiology into feasible implementation. The counseling and other intervention strategies described in this textbook have documented clinical efficacy and cost-effectiveness, and they require little time to learn or implement. The book is written mainly for primary care providers, including general internists and family physicians, but will also be of interest to medical subspecialties such as cardiologists and endocrinologists, as well as medical students, dietitians, psychologists, epidemiologists, and students, practitioners, and researchers in public health. |
| ascvd pooled cohort risk assessment: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults (U.S.), 1998 Of evidence-based recommendations -- Introduction -- Overweight and obesity: background -- Examination of randomized controlled trial evidence -- Treatment guidelines -- Summary of recommendations -- Future research. |
| ascvd pooled cohort risk assessment: Stroke Genetics Hugh S. Markus, 2003 Stroke is a major cause of death and the major cause of adult neurological disability in most of the world. Despite its importance on a population basis, research into the genetics of stroke has lagged behind that of many other disorders. However, the situation is now changing. An increasing number of single gene disorders causing stroke are being described, and there is growing evidence that polygenic factors are important in the risk of apparently sporadic stroke. Stroke Genetics provides an up-to-date review of the area, suitable for clinicians treating stroke patients, and both clinical and non-clinical researchers in the field of cerebrovascular disease. The full range of monogenic stroke disorders causing cerebrovascular disease, including ischaemic stroke, intracerebral haemorrhage, aneurysms and arteriovenous malformations, are covered. For each, clinical features, diagnosis, and genetics are described. Increasing evidence suggest that genetic factors are also important for the much more common multifactorial stroke; this evidence is reviewed along with the results of genetic studies in this area. Optimal and novel strategies for investigating multifactorial stroke, including the use of intermediate phenotypes such as intima-media thickness and MRI detected small vessel disease are reviewed. The book concludes by describing a practical approach to investigating patients with stroke for underlying genetic disorders. Also included is a list of useful websites. |
| ascvd pooled cohort risk assessment: Clinical Lipidology Christie M. Ballantyne, 2009-01-01 Clinical Lipidology, a companion to Braunwald's Heart Disease, is designed to guide you through the ever-changing therapeutic management of patients with high cholesterol levels. From basic science to pathogenesis of atherothrombotic disease, to risk assessment and the latest therapy options, this medical reference book offers unparalleled coverage and expert guidance on lipidology in a straightforward, accessible, and user-friendly style. Get authoritative guidance from some of the foremost experts in the field. Easily access key content with help from treatment algorithms. Access options and evidence-based solutions for every type of patient scenario, as well as the latest clinical guidelines and clinically relevant evidence on risk assessment, special patient populations, and therapy, including recently approved and experimental therapies. Remain at the forefront of the cardiology field with up-to-date chapters on treatment guidelines; diet, exercise, and weight loss; pharmacologic therapies such as statins, omega-3 fatty acids, and combination therapy; evolving targets of therapy such as PCSK9 inhibition, CETP inhibition, and inflammation Prepare for special patient populations such as children and adolescents; women and the elderly; transplant recipients; HIV patients; and those with chronic renal disease, familial hypercholesterolemia, other severe hypercholesterolemias, diabetes, or other metabolic syndromes. Take advantage of a format that follows that of the well-known and internationally recognized Braunwald's Heart Disease. Expert Consult eBook version included with purchase. |
| ascvd pooled cohort risk assessment: Guideline World Health Organization, 2015-12-15 This guideline provides the first global, evidence-informed recommendations on the consumption of potassium to reduce NCDs in most adults and children which WHO had developed. The recommendations in this guideline can be used by policy-makers, technical and program planners in the government and various organizations involved in the design, implementation and scaling-up of nutrition actions for public health and prevention of NCDs, to assess current potassium intake levels relative to a benchmark and develop measures to increase potassium intake, where necessary, through public health interventions including, but not limited to, food and product labelling, consumer education, and the establishment of food-based dietary guidelines (FBDG). The guideline should be used in conjunction with sodium and other nutrient guidelines to develop and guide national policies and public health nutrition programs. |
| ascvd pooled cohort risk assessment: Antiplatelet and Anticoagulation Therapy Albert Ferro, David A. Garcia, 2012-10-13 This title will be presented as highly practical information pn pharmaceutical antiplatelet and anticoagulation therapy, written in a quick-access, no-nonsense format. The emphasis will be on a just-the-facts clinical approach, heavy on tabular material, light on dense prose. The involvement of the ISCP will ensure that the best quality contributors will be involved and establish a consistent approach to each topic in the series. Each volume is designed to be between 120 and 250 pages containing practical illustrations and designed to improve understand and practical usage of cardiovascular drugs in specific clinical areas. |
| ascvd pooled cohort risk assessment: Cardiovascular Calcification Michael Henein, 2022-09-22 The book systematically describes the clinical and scientific aspects of cardiovascular calcification. Chapters detail the mechanisms associated with arterial and valve calcification, relevant risk factors, pathophysiology and the latest therapeutic techniques. Recent diagnostic technological developments including how computed tomography (CT) scanning can be utilized along with Agatston score to quantify coronary arterial calcification when investigating whether a patient for sub-clinical atherosclerosis are covered. The correlation with the presence of arterial calcification and extent of coronary stenosis is also explored. Cardiovasular Calcification details relevant aspects of the basic science and reviews the latest pathological and therapeutic techniques used in treating patients with cardiovascular calcification. It is therefore an essential resource for practicing cardiologists, cardiac surgeons, vascular specialists and radiologists. |
| ascvd pooled cohort risk assessment: Cardiovascular Diseases and Depression Bernhard T. Baune, Phillip J. Tully, 2016-08-01 The world is witnessing a burgeoning global epidemic of chronic cerebro- and cardiovascular disease and depression disorders. The reader will find this comprehensive book to be a long-needed, up-to-date knowledge base on these increasingly recognized comorbid conditions that have long-term consequences for individual function and well-being and society in general. This comprehensive book outlines the complex and bidirectional relationship between various types of depression and cerebro- and cardiovascular diseases. It is written by a range of experts in the field, including psychiatrists, cardiologists, neuroscientists, psychologists, and epidemiologists, with the aim of presenting and discussing the most recent evidence on the pathophysiology, neurobiology, and clinical presentation of these common and disabling comorbid conditions and the available pharmacological, psychological, and behavioral interventions. By elucidating the underlying clinical and neurobiological mechanisms in the brain and the rich interplay between the body and the brain biology, the book brings together the latest knowledge of this overlapping area in Psychiatry and Cardiology. The clear descriptions of evidence-based approaches to clinical treatment ensure that it will serve as both an up-to-date overview and a future guide for practicing clinicians and graduate students. |
| ascvd pooled cohort risk assessment: Cardiovascular Computed Tomography James Stirrup, Russell Bull, Michelle Williams, Ed Nicol, 2020 A practical guide to performing and analysing cardiovascular scans, this handbook is fully updated in this second edition. Containing a wealth of example scan images and detailed guidance on techniques and interpretations, this book is an invaluable workstation resource. |
| ascvd pooled cohort risk assessment: The Atlas of Heart Disease and Stroke Judith Mackay, George A. Mensah, 2004 Heart disease and strokes are currently the leading cause of death in all developed countries and in most developing countries, resulting in one third of all deaths globally in 2003. This publication explores a range of issues relating to this increasingly urgent global health problem using text, colour charts, maps and graphics. Topics covered include: different types of cardiovascular diseases, including rheumatic heart disease; key risk factors including smoking, obesity, physical inactivity, high cholesterol levels and diabetes; risks factors relating to women, childhood and youth; the global burden of coronary heart disease and stroke, and associated economic costs; medical research and funding issues; prevention in personal and public health terms; treatment options; health education; national policies and legislation to address prevention and control; future predictions; chronology of key developments in knowledge of cardiovascular disease; and world data tables. |
| ascvd pooled cohort risk assessment: Patient Care Under Uncertainty Charles F. Manski, 2019-09-10 For the past few years, the author, a renowned economist, has been applying the statistical tools of economics to decision making under uncertainty in the context of patient health status and response to treatment. He shows how statistical imprecision and identification problems affect empirical research in the patient-care sphere. |
| ascvd pooled cohort risk assessment: Decision Making in Health Care Gretchen B. Chapman, Frank A. Sonnenberg, 2000 Decision Making in Health Care, first published in 2000, is a comprehensive overview of the field of medical decision making. |
| ascvd pooled cohort risk assessment: Global Atlas on Cardiovascular Disease Prevention and Control Shanthi Mendis, Pekka Puska, Bo Norrving, World Health Organization, 2011 As the magnitude of cardiovascular diseases (CVDs) continue to accelerate globally, the pressing need for increased awareness and for stronger and more focused international and country responses is increasingly recognized. This atlas on cardiovascular disease prevention and control is part of the response to this need. It documents the magnitude of the problem, using global cardiovascular mortality and morbidity data. It demonstrates the inequities in access to protection, exposure to risk, and access to care as the cause of major inequalities between countries and populations in the occurrence and outcome of CVDs. The report has graphs showing mortality rates of CVDs by age, by country/region, and is divided into three main sections: Section A: Cardiovascular diseases due to atherosclerosis -- Section B: Other cardiovascular diseases -- Section C: Prevention and control of CVDs: Policies, strategies and interventions.--Provided by publisher. |
| ascvd pooled cohort risk assessment: The Role of Nutrition in Maintaining Health in the Nation's Elderly Institute of Medicine, Food and Nutrition Board, Committee on Nutrition Services for Medicare Beneficiaries, 2000-06-09 Malnutrition and obesity are both common among Americans over age 65. There are also a host of other medical conditions from which older people and other Medicare beneficiaries suffer that could be improved with appropriate nutritional intervention. Despite that, access to a nutrition professional is very limited. Do nutrition services benefit older people in terms of morbidity, mortality, or quality of life? Which health professionals are best qualified to provide such services? What would be the cost to Medicare of such services? Would the cost be offset by reduced illness in this population? This book addresses these questions, provides recommendations for nutrition services for the elderly, and considers how the coverage policy should be approached and practiced. The book discusses the role of nutrition therapy in the management of a number of diseases. It also examines what the elderly receive in the way of nutrition services along the continuum of care settings and addresses the areas of expertise needed by health professionals to provide appropriate nutrition services and therapy. |
| ascvd pooled cohort risk assessment: Atlas of Atherosclerosis and Metabolic Syndrome Scott M. Grundy, 2011-03-14 This new edition is an integral source of information on Atherosclerosis. It covers topics such as newer coronary risk factors, high-density lipoprotein metabolism, lipid-lowering drugs, endothelium and thrombosis in atherogenesis, and contributing risk factors. With over 500 exceptional photographs, diagrams, and charts, each chapter illustrates an important facet of diagnosing and treating this common and often fatal disease. |
| ascvd pooled cohort risk assessment: Home Blood Pressure Monitoring George S. Stergiou, Gianfranco Parati, Giuseppe Mancia, 2019-10-31 Hypertension remains a leading cause of disability and death worldwide. Self-monitoring of blood pressure by patients at home is currently recommended as a valuable tool for the diagnosis and management of hypertension. Unfortunately, in clinical practice, home blood pressure monitoring is often inadequately implemented, mostly due to the use of inaccurate devices and inappropriate methodologies. Thus, the potential of the method to improve the management of hypertension and cardiovascular disease prevention has not yet been exhausted. This volume presents the available evidence on home blood pressure monitoring, discusses its strengths and limitations, and presents strategies for its optimal implementation in clinical practice. Written by distinguished international experts, it offers a complete source of information and guide for practitioners and researchers dealing with the management of hypertension. |
| ascvd pooled cohort risk assessment: Clinical Practice Guidelines We Can Trust Institute of Medicine, Board on Health Care Services, Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, 2011-06-16 Advances in medical, biomedical and health services research have reduced the level of uncertainty in clinical practice. Clinical practice guidelines (CPGs) complement this progress by establishing standards of care backed by strong scientific evidence. CPGs are statements that include recommendations intended to optimize patient care. These statements are informed by a systematic review of evidence and an assessment of the benefits and costs of alternative care options. Clinical Practice Guidelines We Can Trust examines the current state of clinical practice guidelines and how they can be improved to enhance healthcare quality and patient outcomes. Clinical practice guidelines now are ubiquitous in our healthcare system. The Guidelines International Network (GIN) database currently lists more than 3,700 guidelines from 39 countries. Developing guidelines presents a number of challenges including lack of transparent methodological practices, difficulty reconciling conflicting guidelines, and conflicts of interest. Clinical Practice Guidelines We Can Trust explores questions surrounding the quality of CPG development processes and the establishment of standards. It proposes eight standards for developing trustworthy clinical practice guidelines emphasizing transparency; management of conflict of interest ; systematic review-guideline development intersection; establishing evidence foundations for and rating strength of guideline recommendations; articulation of recommendations; external review; and updating. Clinical Practice Guidelines We Can Trust shows how clinical practice guidelines can enhance clinician and patient decision-making by translating complex scientific research findings into recommendations for clinical practice that are relevant to the individual patient encounter, instead of implementing a one size fits all approach to patient care. This book contains information directly related to the work of the Agency for Healthcare Research and Quality (AHRQ), as well as various Congressional staff and policymakers. It is a vital resource for medical specialty societies, disease advocacy groups, health professionals, private and international organizations that develop or use clinical practice guidelines, consumers, clinicians, and payers. |
| ascvd pooled cohort risk assessment: Lipids and Cardiovascular Disease , 1990 |
| ascvd pooled cohort risk assessment: Clinical Lipid Management Jennifer G. Robinson, MD, 2023-10-11 Presents the newest thinking and data needed for clinicians to reduce atherosclerotic cardiovascular disease (ASCVD) risk. This book provides detailed evidence-based guidance for treating cholesterol to reduce ASCVD with a focus on recent ACC/AHA guidelines, an overview of evidence-based treatment of other risk factors, the management of genetic and acquired lipid disorders, and complete efficacy and safety information on all available lipid-lowering agents, including clinical trial data and FDA-approved labeling. |
| ascvd pooled cohort risk assessment: Logistic Regression Using the SAS System Paul D. Allison, 2001-12-21 Written in an informal and non-technical style, this book first explains the theory behind logistic regression and then shows how to implement it using the SAS System. Allison includes several detailed, real-world examples of the social sciences to provide readers with a better understanding of the material. He also explores the differences and similarities among the many generalizations of the logistic regression model. |
| ascvd pooled cohort risk assessment: Cardiovascular Diseases Y. Robert Li, 2015-02-25 Written in an accessible style and consistent format, the bookcovers both the fundamentals and advances in the pharmacology ofcardiovascular drugs, as well as their integrated applications inthe management of individual cardiovascular diseases. • Integrates fundamentals and recentadvances regarding cardiovascular drugs, blending basic andclinical sciences needed to effectively understand and treatcardiovascular diseases • Facilitates understanding of drug actionand mechanism by covering physiology / pathophysiology andpharmacology • Includes guidelines and algorithms forpharmacotherapeutic management of cardiovascular diseases • Uses case presentations and studyquestions to enhance understanding of the material • Serves as a resource for pharmaceuticaland medical students and researchers interested in cardiovascularissues |
Low-Dose Colchicine Approved for CVD: Now What? - Medscape
Jun 22, 2023 · The recent US approval of a new low dose of colchicine 0.5 mg (Lodoco; Agepha Pharma) with a broad indication for use in atherosclerotic cardiovascular disease (ASCVD) …
AACE Publishes Guideline on Drug Management of Dyslipidemia
Feb 13, 2025 · It includes 13 evidence-based recommendations for the pharmacologic management of adults with dyslipidemia, focused on patient-important outcomes of ASCVD …
Less TV Time Cuts ASCVD Risk Despite Genetic Risk for T2D
Mar 20, 2025 · The 10-year absolute risk for ASCVD was lower in individuals with high T2D genetic risk who watched ≤ 1 hour of television daily than in those with low T2D genetic risk …
Good Performance for Universal CVD Risk Prediction Model
Feb 12, 2024 · A universal cardiovascular disease (CVD) prediction tool performs well in patients with and without atherosclerotic CVD (ASCVD), a new study showed, suggesting this model …
CHIP Tied to HFpEF and ASCVD: What’s the Link? - Medscape
Feb 2, 2024 · First described as a cancer risk factor, growing evidence links age-related clonal hematopoiesis of indeterminate potential (CHIP) to cardiovascular disease.
Cardiovascular Risk Calculators Fail Some Patients With HIV
Feb 24, 2025 · A common CV risk factor calculator for patients with HIV underestimates risk for Black patients and women, while risk for those in low-income countries is overestimated.
Evidence Builds to Support Colchicine in Treating ASCVD
May 6, 2024 · Colchicine, a legacy drug that received a new indication in 2023 for cardiovascular disease, can treat arterial inflammation after a heart attack, a principal investigator of clinical …
Risk-Calculator Flaws Not Explained by Statin Use - Medscape
Oct 7, 2014 · In an attempt to understand why the WHS cohort had a lower 10-year risk of ASCVD than that using the ACC/AHA risk calculator, researchers asked whether patients …
LDL Not the Primary Culprit in ASCVD? - Medscape
Dec 14, 2020 · LDL cholesterol has been seen as the main offender in ASCVD, but new studies implicate other lipids, including so-called "remnant" cholesterol. An editorial, however, urges …
Statin Use Remains Low for At-Risk Patients - Medscape
Dec 4, 2023 · Expanded prescribing guidelines have not boosted statin use among patients who are at risk for atherosclerotic cardiovascular disease.
Low-Dose Colchicine Approved for CVD: Now What? - Medscape
Jun 22, 2023 · The recent US approval of a new low dose of colchicine 0.5 mg (Lodoco; Agepha Pharma) with a broad indication for use in atherosclerotic cardiovascular disease (ASCVD) …
AACE Publishes Guideline on Drug Management of Dyslipidemia
Feb 13, 2025 · It includes 13 evidence-based recommendations for the pharmacologic management of adults with dyslipidemia, focused on patient-important outcomes of ASCVD …
Less TV Time Cuts ASCVD Risk Despite Genetic Risk for T2D
Mar 20, 2025 · The 10-year absolute risk for ASCVD was lower in individuals with high T2D genetic risk who watched ≤ 1 hour of television daily than in those with low T2D genetic risk …
Good Performance for Universal CVD Risk Prediction Model
Feb 12, 2024 · A universal cardiovascular disease (CVD) prediction tool performs well in patients with and without atherosclerotic CVD (ASCVD), a new study showed, suggesting this model …
CHIP Tied to HFpEF and ASCVD: What’s the Link? - Medscape
Feb 2, 2024 · First described as a cancer risk factor, growing evidence links age-related clonal hematopoiesis of indeterminate potential (CHIP) to cardiovascular disease.
Cardiovascular Risk Calculators Fail Some Patients With HIV
Feb 24, 2025 · A common CV risk factor calculator for patients with HIV underestimates risk for Black patients and women, while risk for those in low-income countries is overestimated.
Evidence Builds to Support Colchicine in Treating ASCVD
May 6, 2024 · Colchicine, a legacy drug that received a new indication in 2023 for cardiovascular disease, can treat arterial inflammation after a heart attack, a principal investigator of clinical …
Risk-Calculator Flaws Not Explained by Statin Use - Medscape
Oct 7, 2014 · In an attempt to understand why the WHS cohort had a lower 10-year risk of ASCVD than that using the ACC/AHA risk calculator, researchers asked whether patients starting …
LDL Not the Primary Culprit in ASCVD? - Medscape
Dec 14, 2020 · LDL cholesterol has been seen as the main offender in ASCVD, but new studies implicate other lipids, including so-called "remnant" cholesterol. An editorial, however, urges …
Statin Use Remains Low for At-Risk Patients - Medscape
Dec 4, 2023 · Expanded prescribing guidelines have not boosted statin use among patients who are at risk for atherosclerotic cardiovascular disease.
